ERYTECH Announces M aximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First -Line Pancreatic Cancer No d ose - l imiting t oxicity (DLT) reported in first two dose cohorts, leading to de c laration of the m aximum t olerated d ose (MTD) at 100 U/kg Encouraging
ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech Cambridge, MA (U.S.) and Lyon (France), September 28 , 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
ERYTECH Announces the A vailability of its H alf- Y ear F inancial R eport 202 1 Lyon (France) a nd Cambridge, MA (U.S.), Septembre 2 2 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 20 2 1 Conference call and webcast on Tuesday, September 21, 2021 at 8:30am EDT / 2:30pm CET TRYbeCA-1 Phase 3 trial of eryaspase in second-line metastatic pancreatic cancer fully enrolled since January
Lyon (France) and Cambridge, MA (U.S.), September 1 5 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second
ERYTECH to Present at the H.C. Wainwright 23 rd Annual Global Investment Conference Cambridge, MA (U.S.) and Lyon (France), September 6 , 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
Monthly information related to total number of voting rights and shares composing the share capital – August 3 1 , 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
Presentation on the lead product candidate eryaspase, L-asparaginase encapsulated in donor-derived red blood cells, featured by KOLs and also the Principal Investigators of the TRYbeCA-1 and rESPECT studies, respectively; Dr. Manuel Hidalgo Medina, M.D., Ph.D., Weill Cornell
ERYTECH to Participate in the Citi 16 th Annual BioPharma Conference Cambridge, MA (U.S.) and Lyon (France), August 30 , 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer Webinar on Wednesday, September 1 st @ 10am ET /4pm CET Cambridge, MA (U.S.) and Lyon (France), August 24 , 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company, leader in red
